- Home
- RSLS vs DRMA Comparison
RSLS vs DRMA Comparison
Compare RSLS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- DRMA
- Stock Information
- Founded
- RSLS 2002
- DRMA 2014
- Country
- RSLS United States
- DRMA United States
- Employees
- RSLS N/A
- DRMA N/A
- Industry
- RSLS Medical/Dental Instruments
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- DRMA Health Care
- Exchange
- RSLS Nasdaq
- DRMA Nasdaq
- Market Cap
- RSLS 4.5M
- DRMA 4.5M
- IPO Year
- RSLS 2007
- DRMA 2021
- Fundamental
- Price
- RSLS $2.56
- DRMA $0.63
- Analyst Decision
- RSLS Hold
- DRMA Strong Buy
- Analyst Count
- RSLS 1
- DRMA 1
- Target Price
- RSLS N/A
- DRMA $3.00
- AVG Volume (30 Days)
- RSLS 7.3M
- DRMA 81.1K
- Earning Date
- RSLS 08-13-2025
- DRMA 08-06-2025
- Dividend Yield
- RSLS N/A
- DRMA N/A
- EPS Growth
- RSLS N/A
- DRMA N/A
- EPS
- RSLS N/A
- DRMA N/A
- Revenue
- RSLS $7,175,000.00
- DRMA N/A
- Revenue This Year
- RSLS $52.80
- DRMA N/A
- Revenue Next Year
- RSLS N/A
- DRMA N/A
- P/E Ratio
- RSLS N/A
- DRMA N/A
- Revenue Growth
- RSLS N/A
- DRMA N/A
- 52 Week Low
- RSLS $2.23
- DRMA $0.64
- 52 Week High
- RSLS $414.99
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- RSLS 36.91
- DRMA 30.33
- Support Level
- RSLS $2.45
- DRMA $0.65
- Resistance Level
- RSLS $2.87
- DRMA $0.73
- Average True Range (ATR)
- RSLS 0.68
- DRMA 0.05
- MACD
- RSLS 0.14
- DRMA -0.00
- Stochastic Oscillator
- RSLS 5.45
- DRMA 1.18
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.